GUTS vs. LYRA, CVRX, CERS, TCMD, LUNG, BVS, NPCE, SGHT, TLSI, and SRDX
Should you be buying Fractyl Health stock or one of its competitors? The main competitors of Fractyl Health include Lyra Therapeutics (LYRA), CVRx (CVRX), Cerus (CERS), Tactile Systems Technology (TCMD), Pulmonx (LUNG), Bioventus (BVS), NeuroPace (NPCE), Sight Sciences (SGHT), TriSalus Life Sciences (TLSI), and Surmodics (SRDX). These companies are all part of the "surgical & medical instruments" industry.
Lyra Therapeutics (NASDAQ:LYRA) and Fractyl Health (NASDAQ:GUTS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, community ranking, valuation and profitability.
Lyra Therapeutics received 18 more outperform votes than Fractyl Health when rated by MarketBeat users. However, 100.00% of users gave Fractyl Health an outperform vote while only 70.00% of users gave Lyra Therapeutics an outperform vote.
In the previous week, Lyra Therapeutics and Lyra Therapeutics both had 3 articles in the media. Lyra Therapeutics' average media sentiment score of 0.35 beat Fractyl Health's score of 0.07 indicating that Fractyl Health is being referred to more favorably in the news media.
Lyra Therapeutics presently has a consensus target price of $12.67, suggesting a potential upside of 168.36%. Fractyl Health has a consensus target price of $22.00, suggesting a potential upside of 228.36%. Given Lyra Therapeutics' higher probable upside, analysts plainly believe Fractyl Health is more favorable than Lyra Therapeutics.
95.6% of Lyra Therapeutics shares are owned by institutional investors. 17.4% of Lyra Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Fractyl Health has a net margin of 0.00% compared to Fractyl Health's net margin of -4,023.11%. Lyra Therapeutics' return on equity of 0.00% beat Fractyl Health's return on equity.
Lyra Therapeutics has higher revenue and earnings than Fractyl Health.
Summary
Fractyl Health beats Lyra Therapeutics on 7 of the 13 factors compared between the two stocks.
Get Fractyl Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for GUTS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GUTS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Fractyl Health Competitors List
Related Companies and Tools
